IAPP and type 1 diabetes mellitus: Exogenous insulin treatment and normalization of glycemia in T1D cannot reverse increased glucagon secretion (see “Glucagon, Islet Amyloid Polypeptide”) and, therefore, targeting hyperglucagonemia with GLP-1RAs could be a useful therapeutic intervention (159).